A carregar...

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT

Na minha lista:
Detalhes bibliográficos
Publicado no:HemaSphere
Main Authors: Anjali Cremer, Julius C. Enssle, Saskia Pfaff, Khouloud Kouidri, Fabian Lang, Christian Brandts, Andreas Zeiher, Sebastian Cremer, Björn Steffen, Hubert Serve, Gesine Bug
Formato: Artigo
Publicado em: Wiley 2023-08-01
Acesso em linha:http://journals.lww.com/10.1097/01.HS9.0000972164.39454.e5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!